The notices it replaced
Its page was not saved, so the notices it replaced are not known.
Who won it before
2 competing awards (new and renewals) from FY2014 to FY2025 under this notice and the notices it replaced: $553,709 in first-year total cost, median $276,855.
Most frequent study sections
- Risk, Prevention and Intervention for Addictions Study Section[RPIA]1
- Special Emphasis Panel[ZRG1 AARR-N (02)]1
Most frequent institutions
- BRIGHAM AND WOMEN'S HOSPITAL1
- PUBLIC HEALTH FOUNDATION ENTERPRISES1
| FY | Project | PIs | Institution | First-year cost | Study section |
|---|---|---|---|---|---|
| 2018 | Development and Pilot Testing of a Persuasive Health Communication Intervention for Emergency Department Patients Who Decline Rapid HIV/HCV Screening1R34DA045544-01 | MERCHANT, ROLAND C | BRIGHAM AND WOMEN'S HOSPITAL, MA | $360,256 | ZRG1 |
| 2015 | Hepatitis C Treatment As Prevention Pilot Study with Ledipasvir-Sofosbuvir Among People Actively Injecting Drugs (TasP-C Pilot)1R34DA039333-01A1 | COFFIN, PHILLIP O | PUBLIC HEALTH FOUNDATION ENTERPRISES, CA | $193,453 | RPIA |
Data: Grants.gov's daily extract and NIH's notice pages and award files, in ScienceGraph release conductgrants-2026-11-09-0.1.0. An award is listed only where NIH's own record names the notice, and a PI only by NIH's profile ID. Grants.gov and NIH do not endorse ScienceDex.